Digital health technologies (DHTs) – connected watches, sensors, mobile applications, wearable medical devices – are often described as a revolution in clinical research. They allow continuous patient monitoring, capture weak signals impossible to detect during hospital visits, and bring “real-life” data into clinical studies. Yet despite their promise, their integration into clinical trials faces a far more complex regulatory reality than expected.
Digital health technologies: ten years of European experience, mixed record
A recent study published in Drug Discovery Today reviewed ten years of interactions between the European Medicines Agency (EMA) and sponsors on digital health technologies. Between 2013 and 2022, the EMA issued 81 scientific advices, 14 qualification opinions, and only 2 public statements regarding digital endpoints derived from DHTs.
The most commonly proposed devices were accelerometers (mobility, sleep, fatigue), followed by continuous glucose monitors and smartphones. Therapeutic areas reflected unmet needs: neurological diseases, metabolic disorders, and rare diseases, where DHTs provide solutions to the lack of objective measures.
The outcome remains modest: in ten years, only two digital endpoints were officially qualified by the EMA. This shows how validation remains a major barrier.
Why so little official recognition?
Evaluation of digital health technologies by authorities is based on strict criteria:
- Validation and accuracy: the measurement must be reproducible, sensitive, and specific.
- Context of use: the same sensor may be relevant for one indication but insufficient for others.
- Clinical relevance: the digital measure must translate into a tangible effect on patient health and add value compared with existing measures.
- Patient impact: a digital endpoint that fatigues or excludes participants does not bring real benefit.
In summary, DHTs are no regulatory shortcut. They must meet the same robustness standards as traditional endpoints.
Opportunities and challenges for sponsors
The rise of DHTs must be understood strategically. For a pharmaceutical company or biotech, the benefit is not only scientific: it is also about anticipating regulatory agencies’ and market access bodies’ expectations.
Health authorities do not merely evaluate technological innovation: they need to ensure that its contribution will be recognized in medico-economic assessments. A poorly defined or insufficiently validated endpoint risks blocking both Marketing Authorization (MA) and the crucial reimbursement phase. For BluePharm, this is exactly where the challenge lies: supporting companies in designing clinical trials where digital endpoints are integrated from the start as tools for both clinical and economic demonstration.
Use cases that show the way forward
Some examples demonstrate that DHTs can obtain regulatory approval. The measurement of stride velocity (95th centile) in Duchenne muscular dystrophy patients using wearable sensors was recognized by the EMA as a secondary, then primary, endpoint.
This success illustrates the method to follow: define a precise context, document the added value compared to existing standards, and demonstrate technical feasibility.
Rare diseases, where the limited number of patients requires maximizing every collected data point, represent another promising field. DHTs here provide a unique opportunity for remote and continuous disease monitoring.
Towards regulatory legitimacy for DHTs
For innovators, three key recommendations emerge:
- Think endpoint before device: the sensor is not the goal, only the clinically relevant measurement it enables matters.
- Engage early with regulators: initiate early dialogue through Qualification of Novel Methodologies procedures to avoid costly dead ends.
- Integrate patients at the center: a technology that complicates daily life or excludes participants will never achieve broad adoption.
Why this matters for market access
The past decade has shown that without rigorous validation, DHTs remain seen as gadgets. But when intelligently integrated into protocols, they become powerful tools for demonstrating both clinical and economic value.
This is exactly where BluePharm positions its expertise: helping stakeholders anticipate regulatory expectations and design clinical trials where technological innovation directly supports market access.
Ultimately, the regulatory legitimacy of digital health technologies will not come from technological appeal, but from their ability to generate solid, relevant evidence recognized by both regulators and payers.
